|Acanthosis nigricans on axilla|
|Symptoms||Dark brown-black, poorly defined, velvety patches of the skin, typically on face, neck, underarms|
|Differential diagnosis||Intertriginous granular parakeratosis|
Acanthosis nigricans appears as dark brown-black, poorly defined, velvety patches of the skin, typically affecting the face, neck, underarms, genitals, groin elbows, knees, anus, umbilicus and nasal crease. Palms and soles may be thick with prominence of palmar creases. It is usually found in body folds. Types include acanthosis nigricans associated with malignancy, familial acanthosis nigricans and Fgfr gene mutation syndromes, acanthosis nigricans associated with insulin-resistant states and syndromes, drug induced acanthosis nigricans and miscellaneous types.
It is associated with endocrine dysfunction, especially insulin resistance and hyperinsulinaemia, as seen in diabetes mellitus. This activates the insulin-like growth factor receptors, which leads to proliferation of keratinocytes, fibroblasts and other cells in the skin. Activation of other growth factor receptors such as fibroblast growth factor receptors or epidermal growth factor receptor can also be responsible.
Signs and symptoms
Acanthosis nigricans may present with thickened, velvety, relatively darker areas of skin on the neck, armpit and in skin folds.
It typically occurs in individuals younger than age 40, may be genetically inherited and is associated with obesity or endocrinopathies, such as hypothyroidism, acromegaly, polycystic ovary disease, insulin-resistant diabetes or Cushing's disease.
Type I – familial
Familial acanthosis: 86 may arise as a result of an autosomal dominant trait, presenting at birth or developing during childhood.: 506 : 676
Type II – endocrine
Endocrine syndromes associated with acanthosis nigricans: 506–7 can develop in many conditions, particularly:: 978 : 86
- starts with insulin resistance, such as diabetes mellitus and metabolic syndrome
- excess circulating androgens, particularly Cushing's disease, acromegaly, polycystic ovarian disease
- Addison's disease and hypothyroidism
- Rare diseases, including pinealoma, leprechaunism, lipoatrophic diabetes, pineal hyperplasia syndrome, pituitary basophilism, ovarian hyperthecosis, stromal luteoma, ovarian dermoid cysts, Prader-Willi syndrome, and Alström syndrome.
Acanthosis nigricans associated with endocrine dysfunction is more insidious in its onset, is less widespread, and the patients are often concurrently obese.: 676
Type III – obesity and pseudoacanthosis nigricans
In young persons, acanthosis nigricans is a visible marker which strongly suggests insulin resistance. Higher than normal insulin levels in the blood stream cause the growth of darkened skin over certain areas of the body. No skin treatment will get rid of AN. Acanthosis nigricans may lighten up and possibly go away by treating the root cause, insulin resistance, but it can take months or years to do so. Insulin resistance syndromes may be divided into type A (HAIR-AN) and type B syndromes.: 978
The majority of cases of acanthosis nigricans are associated with obesity and otherwise idiopathic. This is likely because of insulin resistance and more likely to occur in darker-skinned persons.: 968 This can also be referred to as pseudoacanthosis nigricans.: 86 In some cases, AN attributable to obesity and insulin resistance will occur on ones face. Most typically it will be present as a horizontal band on the forehead, but may also appear as perioral hyperpigmentation, periorbital hyperpigmentation, or generalized facial skin darkening.
Acanthosis nigricans has been linked to the use of nicotinic acid, glucocorticoid use, combined oral contraceptive pills, and growth hormone therapy.: 86
Type V – malignancy
Malignant acanthosis nigricans: 86 refers to acanthosis nigricans occurring as a paraneoplastic syndrome associated with a cancer. Malignant acanthosis nigricans is most commonly associated with gastrointestinal adenocarcinomas, as well as genitourinary cancers such as those of the prostate, breast, and ovary. Other cancers, such as those of the lung, stomach, and lymphoma, are occasionally associated with acanthosis nigricans.: 86 
This form of acanthosis nigricans is more likely to involve mucous membranes (25–50% of cases) Malignant acanthosis nigricans that may either precede (18%), accompany (60%), or follow (22%) the onset of an internal cancer.: 506 Malignancy-associated acanthosis nigricans is usually rapid in onset and may be accompanied by skin tags, multiple seborrheic keratoses, or tripe palms.: 676
Acral acanthotic anomaly
Acral acanthotic anomaly refers to a variant of acanthosis nigricans limited to the elbows, knees, knuckles, and dorsal surfaces of the feet, in the absence of any other findings, in otherwise healthy individuals. While the etiology remains unknown, its presence does not suggest a likelihood of malignancy.
Acanthosis nigricans is caused by increased activation of growth factor receptor proteins, usually due to endocrine dysfunction. This is most commonly insulin-mediated activation of IGF receptors on keratinocytes, as a result of hyperinsulinaemia or insulin resistance, as seen in diabetes mellitus.
Factors involved in the development of acanthosis nigricans include:
- Increased circulating insulin. This activates keratinocyte IGF receptors, particularly IGF-1. At high concentrations, insulin may also displace IGF-1 from insulin-like growth factor-binding protein (IGFBP). Increased circulating IGF may lead to keratinocyte and dermal fibroblast proliferation.
- In hereditary forms of acanthosis nigricans, fibroblast growth factor receptor (FGFR) defects
- Increased transforming growth factor (TGF), which appears to be the mechanism for malignancy-associated acanthosis nigricans. TGF acts on epidermal tissue via the epidermal growth factor receptor (EGFR).: 86
In conjunction with increased end levels of IGF, it is likely that perspiration and friction may be necessary predeterminants for lesions, since the level of insulin is usually not enough to activate IGF receptors across the body.
Acanthosis nigricans is typically diagnosed clinically. A skin biopsy may be needed in unusual cases. If no clear cause is obvious, it may be necessary to search for one. Blood tests, an endoscopy, or X-rays may be required to eliminate the possibility of diabetes or cancer as the cause.: 87
On biopsy, hyperkeratosis, epidermal folding, leukocyte infiltration, and melanocyte proliferation may be seen.: 979 : 87
Acanthosis nigricans should be distinguished from the casal collar appearing in pellagra.
Acanthosis nigricans is conventionally divided into benign and malignant forms, although may be divided into syndromes according to cause:: 506
- Benign This may include obesity-related, hereditary, and endocrine forms of acanthosis nigricans.
- Malignant. This may include forms that are associated with tumour products and insulin-like activity, or tumour necrosis factor.
An alternate classification system still used to describe acanthosis nigricans was proposed in 1994. It delineates acanthosis nigricans syndromes according to their associated syndromes, including benign and malignant forms, forms associated with obesity and drugs, acral acanthosis nigricans, unilateral acanthosis nigricans, and mixed and syndromic forms.
People with acanthosis nigricans should be screened for diabetes and, although rare, cancer. Controlling blood glucose levels through exercise and diet often improves symptoms. Topical fade creams (normally used for eliminating age spots) can lighten skin cosmetically in less severe cases. Selenium sulfide topical 2 percent applied in thin layer to dry skin ten minutes prior to bathing may clear symptoms. Selenium sulfide applied to dry scalp or skin is an inexpensive well tolerated treatment to balance skin's biome and works by drying fungus like tinea versicolor that can coexist with acanthosis and exacerbate discoloration. Acanthosis nigricans maligna may resolve if the causative tumor is successfully removed.
Acanthosis nigricans is likely to improve in circumstances where a known cause is removed. For example, obesity-related acanthosis nigricans will improve with weight loss, and drug-induced acanthosis nigricans is likely to resolve when the drug is ceased. Hereditary variants may or may not fade with age, and malignancy-associated variants may, after a malignancy is removed, fade. : 87
- ↑ 1.0 1.1 1.2 1.3 1.4 James, William D.; Elston, Dirk; Treat, James R.; Rosenbach, Misha A.; Neuhaus, Isaac (2020). "24. Endocrine diseases". Andrews' Diseases of the Skin: Clinical Dermatology (13th ed.). Elsevier. p. 502-5504. ISBN 978-0-323-54753-6. Archived from the original on 2021-10-17. Retrieved 2021-10-17.
- ↑ "acanthosis nigricans" at Dorland's Medical Dictionary
- ↑ 3.0 3.1 3.2 3.3 3.4 Higgins, SP; Freemark, M; Prose, NS (Sep 15, 2008). "Acanthosis nigricans: a practical approach to evaluation and management". Dermatology Online Journal. 14 (9): 2. PMID 19061584.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 Habif, Thomas P. (2009). Clinical dermatology (5th ed.). Edinburgh: Mosby. ISBN 978-0-7234-3541-9.
- ↑ "Acanthosis nigricans - Symptoms and causes". Mayo Clinic. Archived from the original on 2021-08-13. Retrieved 2021-08-13.
- ↑ "What Is Acanthosis Nigricans?". WebMD. Archived from the original on 2021-08-12. Retrieved 2021-08-13.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 Thomas B. Fitzpatrick; et al. (2005). Fitzpatrick's color atlas and synopsis of clinical dermatology (5th ed.). New York: McGraw-Hill Medical Pub. Division. ISBN 978-0-07-144019-6.
- ↑ 8.0 8.1 8.2 8.3 James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0-7216-2921-0.
- ↑ 9.0 9.1 9.2 Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 978-1-4160-2999-1.
- ↑ "Nueces County Medical Society | Health Education - Insulin Resistance and Acanthosis Nigricans in Kids". www.nuecesmedsociety.org. 2018-04-12. Archived from the original on 2018-04-12. Retrieved 2020-03-01.
- ↑ Verma, Shyam; Vasani, Resham; Joshi, Rajiv; Phiske, Meghana; Punjabi, Pritesh; Toprani, Tushar (2016). "A descriptive study of facial acanthosis nigricans and its association with body mass index, waist circumference and insulin resistance using HOMA2 IR". Indian Dermatology Online Journal. 7 (6): 498–503. doi:10.4103/2229-5178.193898. ISSN 2229-5178. PMC 5134163. PMID 27990384.
- ↑ Rigel DS; Jacobs MI (1980). "Malignant acanthosis nigricans:a review". The Journal of Dermatologic Surgery and Oncology. 6 (11): 923–7. doi:10.1111/j.1524-4725.1980.tb01003.x. PMID 6257767.
- ↑ 13.0 13.1 Ngan, Vanessa. "Acanthosis nigricans". Archived from the original on 11 November 2013. Retrieved 23 August 2013.
- ↑ Schnopp C; Baumstark J (2007). "Oral acanthosis nigricans". N Engl J Med. 357 (9): e10. doi:10.1056/NEJMicm062917. PMID 17761587.
- ↑ Schwartz RA (February 2007). "Acral acanthosis nigricans (acral acanthotic anomaly)". J. Am. Acad. Dermatol. 56 (2): 349–50. doi:10.1016/j.jaad.2006.09.027. PMID 17224380.
- ↑ Schwartz RA (September 1981). "Acral acanthotic anomaly (AAA)". J. Am. Acad. Dermatol. 5 (3): 345–6. doi:10.1016/S0190-9622(81)80155-7. PMID 7263979.
- ↑ Schwartz RA (July 1994). "Acanthosis nigricans". J. Am. Acad. Dermatol. 31 (1): 1–19, quiz 20–2. doi:10.1016/S0190-9622(94)70128-8. PMID 8021347.
- ↑ 18.0 18.1 18.2 Tilgen W (2009). "Benign epidermal tumors". In WHC Burgdorf; G Plewig; HH Wolff; M Landthaler; O Braun-Falco (eds.). Braun-Falco's Dermatology (3rd ed.). Heidelberg: Springer. pp. 1340–7. ISBN 978-3-540-29312-5.
- ↑ Garofalo, L.; A.M. Biscozzi; V. Mastrandrea; E. Bonifazi (2003). "Acanthosis nigricans vulgaris. A marker of hyperinsulinemia" (PDF). Eur. J. Pediat. Dermatol. 13: 85–8. Archived from the original (PDF) on 2011-07-09. Retrieved 2010-07-29.
- ↑ Schwartz, Robert A. (1994). "Acanthosis nigricans". Journal of the American Academy of Dermatology. 31 (1): 1–19. doi:10.1016/S0190-9622(94)70128-8. PMID 8021347.
- ↑ Brown J; Winkelmann RK (1968). "Acanthosis nigricans: study of 90 cases". Medicine. 47 (1): 33–51. doi:10.1097/00005792-196801000-00002. PMID 4868603. S2CID 2241453.